Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment

Introduction and aim. Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF). The efficacy and safety of treating such relapsers using ledipasvir/sofosbuvir (LDV/SOF) with/wit...

Full description

Bibliographic Details
Main Authors: Bashar Aqel, Michael Leise, Hugo E. Vargas, Kymberly D. Watt, Andrew P. Keaveny, Nan Zhang, Surakit Pungpapong
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:Annals of Hepatology
Subjects:
Hepatitis C
Direct acting antiviral agents (DAA)
Simeprevir
Sofosbuvir
Ledipasvir
Relapser
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119302601

Internet

http://www.sciencedirect.com/science/article/pii/S1665268119302601

Similar Items